UNSPSC 51295001: Atibeprone

This classification denotes an antidepressant agent with the molecular formula C17H18N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PZV3P03F1U, chemically known as 7-((5-isopropyl-1,3,4 thiadiazol-2-yl)methoxy)-3,4-dimethylcoumarin but generally known as atibeprone, which bears US NIH Compound Identifier 179342. European Medicines Agency schedules Atibeprone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05593MIG.

UNSPSC 51295001 Atibeprone (Commodity) shows limited recent state and local procurement activity directly aligned with the code's pharmaceutical scope. The source documents three opportunities tagged under this code, but only one—Seminole County's naloxone and drug deactivation systems purchase—represents a direct pharmaceutical or medical-supply procurement matching the code's nominal product category. The other two opportunities (Texas HHS Commission's RFI on direct-to-manufacturer prescriptions and MMCAP's generic multi-source pharmaceuticals cooperative) address broader pharmaceutical procurement frameworks, supply-chain models, and OTC product distribution rather than the specific active pharmaceutical ingredient or finished-goods product this code nominally covers. State and local bodies using this code span county health departments (Seminole County), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP), indicating that pharmaceutical procurement at the state and local level is fragmented across direct purchasing, cooperative vehicles, and exploratory procurement mechanisms.

Seminole County, Florida, released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023 (note: date discrepancy in source), delivered quarterly to the Seminole County Community Health Building in Sanford with a two-year initial term and one-year renewal option. The Texas RFI (HHS0017013), posted April 3, 2026, represents exploratory procurement rather than a binding solicitation, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO channels. MMCAP's RFP (S1070000015802) for generic pharmaceuticals and OTC products, due March 26, 2026, targets multi-state distribution through three authorized wholesalers with an effective date of July 1, 2026, weighted heavily on price competitiveness (75 percent). The three opportunities together span Florida, Texas, and the Minnesota-administered MMCAP region (including Oregon), but the code shows modest transaction volume relative to broader pharmaceutical procurement activity occurring under different UNSPSC classifications or cooperative purchasing vehicles.